Cargando…

Paxlovid (Nirmatrelvir and Ritonavir) Use in Pregnant and Lactating Woman: Current Evidence and Practice Guidelines—A Scoping Review

COVID-19 virus, since the detection of the first case in Wuhan in 2019, has caused a worldwide pandemic with significant human, economic and social costs. Fortunately, several vaccines and treatments, both IV and oral, are currently approved against the COVID-19 virus. Paxlovid is an oral treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chourasia, Prabal, Maringanti, Babu Sriram, Edwards-Fligner, Morgan, Gangu, Karthik, Bobba, Aniesh, Sheikh, Abu Baker, Shekhar, Rahul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866309/ https://www.ncbi.nlm.nih.gov/pubmed/36679952 http://dx.doi.org/10.3390/vaccines11010107

Ejemplares similares

COVID-19 and Acute Ischemic Stroke Mortality and Clinical Outcomes among Hospitalized Patients in the United States: Insight from National Inpatient Sample
por: Davis, Monique G., et al.
Publicado: (2023)

Gender and Race-Based Health Disparities in COVID-19 Outcomes among Hospitalized Patients in the United States: A Retrospective Analysis of a National Sample
por: Pal, Suman, et al.
Publicado: (2022)

Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022
por: Bihan, Kevin, et al.
Publicado: (2023)

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
por: Sánchez Fabra, David, et al.
Publicado: (2023)

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
por: Sánchez Fabra, David, et al.
Publicado: (2023)

Nationwide Analysis of the Clinical Outcomes of Patients Admitted With COVID-19 Infection With Myocarditis and Racial Disparities in Mortality
por: Cannon, Harmon R, et al.
Publicado: (2023)

Impact of COVID-19 on Patients Hospitalized with ST-Segment Elevation Myocardial Infarction in the United States during the Early Pandemic: An Analysis of Outcomes, Care Delivery, and Racial Disparities in Mortality
por: Majeed, Harris, et al.
Publicado: (2023)

COVID-19 Associated Myocarditis Clinical Outcomes among Hospitalized Patients in the United States: A Propensity Matched Analysis of National Inpatient Sample
por: Davis, Monique G., et al.
Publicado: (2022)

COVID-19 and Pulmonary Embolism Outcomes among Hospitalized Patients in the United States: A Propensity-Matched Analysis of National Inpatient Sample
por: Nasrullah, Adeel, et al.
Publicado: (2022)

COVID-19 and Influenza Coinfection Outcomes among Hospitalized Patients in the United States: A Propensity Matched Analysis of National Inpatient Sample
por: Garg, Ishan, et al.
Publicado: (2022)

Tacrolimus Drug–Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin
por: Sindelar, Morganne, et al.
Publicado: (2022)

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
por: Hashemian, Seyed Mohammad Reza, et al.
Publicado: (2023)

COVID-19 and NSTEMI Outcomes among Hospitalized Patients in the United States and Racial Disparities in Mortality: Insight from National Inpatient Sample Database
por: Majeed, Harris, et al.
Publicado: (2022)

Le nirmatrelvir-ritonavir (Paxlovid®), un traitement contre la Covid-19
por: Buxeraud, Jacques, et al.
Publicado: (2022)

Comment on “Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin”
por: de Oliveira, Luciana Mello, et al.
Publicado: (2023)

Response to Comment on “Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin”
por: Sindelar, Morganne, et al.
Publicado: (2023)

Drug Interaction Between Tacrolimus and Paxlovid (Nirmatrelvir/Ritonavir) in an Adolescent with Inflammatory Bowel Disease
por: Zaarur, Leenoy, et al.
Publicado: (2023)

Thirty-Day readmissions among COVID-19 patients hospitalized during the early pandemic in the United States: Insights from the Nationwide Readmissions Database
por: Muzammil, Taimur Sohail, et al.
Publicado: (2023)

Paxlovid-Induced Symptomatic Bradycardia and Syncope
por: Ganipisetti, Venu M, et al.
Publicado: (2023)

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
por: Marzolini, Catia, et al.
Publicado: (2022)

511. Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment For COVID-19
por: Bhargava, Ashish, et al.
Publicado: (2023)

Comparative Analysis of Clinical Outcomes for COVID-19 and Influenza among Cardiac Transplant Recipients in the United States
por: Chavarin, Daniel J., et al.
Publicado: (2023)

WCN23-0117 PAXLOVID ( NIRMATRELVIR/RITONAVIR ) AND CYCLOSPORIN IN A KIDNEY TRANSPLANT PATIENT WITH COVID-19 INFECTION
por: Then, R.F., et al.
Publicado: (2023)

Treatment of acute tacrolimus toxicity with phenytoin after Paxlovid (nirmatrelvir/ritonavir) administration in a kidney transplant recipient
por: Kwon, Eun-Jeong, et al.
Publicado: (2022)

Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations
por: Cohen, Alison K., et al.
Publicado: (2023)

COVID-19 Alcoholic Cirrhosis and Non-Alcoholic Steatohepatitis Cirrhosis Outcomes among Hospitalized Patients in the United States: Insight from National Inpatient Sample Database
por: Kapuria, Devika, et al.
Publicado: (2022)

Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer
por: Anwar, Kaleem, et al.
Publicado: (2022)

COVID-19 With Stress Cardiomyopathy Mortality and Outcomes Among Patients Hospitalized in the United States: A Propensity Matched Analysis Using the National Inpatient Sample Database
por: Davis, Monique G., et al.
Publicado: (2023)

Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant
por: Young, Chelsea, et al.
Publicado: (2022)

The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between M(pro) and antiviral drugs (nirmatrelvir and ritonavir)
por: Dawood, Ali Adel
Publicado: (2023)

Trends in Hospitalization and Mortality for Influenza and Other Respiratory Viruses during the COVID-19 Pandemic in the United States
por: Nasrullah, Adeel, et al.
Publicado: (2023)

528. Matched Retrospective Study, Comparing Molnupiravir to Nirmatrelvir-Ritonavir (Paxlovid) in the Treatment of Mild-Moderate COVID-19 in Immunocompromised Cancer Patients
por: Haddad, Andrea, et al.
Publicado: (2023)

Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022)

Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022)

A sustainable synthesis of the SARS-CoV-2 M(pro) inhibitor nirmatrelvir, the active ingredient in Paxlovid
por: Kincaid, Joseph R. A., et al.
Publicado: (2022)

Nirmatrelvir más ritonavir (Paxlovid) una potente combinación inhibidora de la proteasa 3CLpro del SARS-CoV-2
por: Reina, Jordi, et al.
Publicado: (2022)

Effect of Nirmatrelvir/Ritonavir (Paxlovid) on Hospitalization among Adults with COVID-19: an EHR-based Target Trial Emulation from N3C
por: Bhatia, Abhishek, et al.
Publicado: (2023)

A 1-Pot Synthesis of the SARS-CoV-2 M(pro) Inhibitor Nirmatrelvir, the Key Ingredient in Paxlovid
por: Caravez, Juan C., et al.
Publicado: (2022)

COVID-19 and Heart Failure with Preserved and Reduced Ejection Fraction Clinical Outcomes among Hospitalized Patients in the United States
por: Nasrullah, Adeel, et al.
Publicado: (2023)

Outcomes of Diabetic Ketoacidosis in Adults With End-Stage Kidney Disease: Retrospective Study Based on a National Database
por: Gangu, Karthik, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_14d4oblld5scvufusacph64o9d